| Patient | Georgia O'Keeffe |
|---|---|
| Date of birth | 1945-11-15 |
| Identifiers | MRN HR-ET011-SYN; SSN (made up) 000-11-5873 |
| Document date | 2026-05-07 |
| Author | Wendell Ashby, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Third loading injection and end-of-loading review, left eye. [S]
Ms. O'Keeffe returns four weeks after her second injection, eight weeks after starting treatment. Straight lines look nearly straight again with the left eye, and she can read newspaper headlines and judge color in the studio better than in March. She has had no pain, redness, or loss of vision after either injection. Daily Amsler checks show no change in the right eye. She takes the AREDS2 supplement daily. Her low-vision rehabilitation evaluation took place this month, and the home visit and driving assessment are under way. [S]
| Element | Detail |
|---|---|
| Interval change | Distortion nearly gone in the left eye; color judgment better |
| Injection tolerance | No pain, redness, or vision loss after two injections |
| Amsler grid | Daily checks; right eye unchanged |
| Low-vision rehabilitation | Evaluation done; home visit and driving assessment under way |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Slight residual blur in the left eye; no pain, flashes, or floaters |
| Constitutional | Negative | Weight stable; good energy |
| Musculoskeletal | Negative | No falls |
| Psychiatric | Negative | Mood good; painting daily |
4 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-07 | Body height | 165 | cm | S |
| 2026-05-07 | Body weight | 56 | kg | S |
| 2026-05-07 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-05-07 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-05-07 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-05-07 | Heart rate | 68 | /min | S |
| 2026-05-07 | Respiratory rate | 14 | /min | S |
| 2026-05-07 | Body temperature | 36.6 | Cel | S |
| 2026-05-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-07 | Visual acuity best corrected Left eye by ETDRS eye chart | 69 | {letters} | >=80 | Low | S |
| 2026-05-07 | Macular grid.center subfield thickness by OCT | 274 | um | 200-300 um | Normal | S |
| 2026-05-07 | Left eye Intraocular pressure | 14 | mm[Hg] | 10-21 mmHg | Normal | S |
Vital signs recorded on 2026-05-07; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Visual acuity | Best-corrected 69 letters left, up from 55 |
| Intraocular pressure | 14 mmHg left before injection |
| Anterior segment | Quiet |
| Dilated fundus, left eye | Lesion flat, with no fluid or hemorrhage |
| Dilated fundus, right eye | Large drusen unchanged; no fluid or hemorrhage |
| OCT, left eye | Dry macula; central subfield thickness 274 µm |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Neovascular (wet) age-related macular degeneration, left eye, with active choroidal neovascularization | active | confirmed | H35.3221 | S — Synthetic modern diagnosis linked to her documented failing eyesight; the historical type of macular degeneration is not recorded. |
| Nonexudative age-related macular degeneration, right eye, intermediate stage | active | confirmed | H35.3112 | S — Synthetic finding in the fellow eye. |
| New distortion (wavy lines) and a blurred central spot with reduced acuity in the left eye; suspected neovascular macular degeneration, urgent retina referral | resolved | confirmed | H53.15 | S — Synthetic presenting concern at the index visit, superseded by the OCT diagnosis at the retina consultation; her failing eyesight is documented (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | Left 69 letters, up 14 from baseline; loading goal met |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Left eye dry; central subfield thickness 274 µm |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 14 mmHg left; after injection, optic nerve perfused and counting fingers |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen unchanged; no fluid |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | No complication after three injections; last loading dose today |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Reviewed again before the longer interval |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Daily checks recorded; no change in the right eye |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Taking it daily |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Referred | Evaluation done this month; home visit and driving assessment under way |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Due | Planned at the July primary care review |
Goal progress:
Guideline basis: Age-Related Macular Degeneration Preferred Practice Pattern (2024); CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026)
Follow-up: Retina visit in eight weeks, with the primary care review of vision rehabilitation on the same day. Next scheduled visit 2026-07-02: treat-and-extend retina visit and primary care review of vision rehabilitation. [S]